Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Tampere University Hospital
- Enrollment
- 37
- Locations
- 2
- Primary Endpoint
- ctDNA level
Study Overview
Brief Summary
Circulating tumour DNA (ctDNA) is a promising tool when monitoring the residual disease in colorectal cancer (CRC). Current staging procedures are insufficient to identify the patient cohort at high risk, who might benefit from additional adjuvant therapy.
We will show that the assessment of ctDNA is a non-invasive approach and easily taken at different time points via simple blood draw to monitor residual disease from the colorectal cancer patients after primary surgery. Minimal residual disease could be used in the future for individualized treatment decisions after primary surgery.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •planned colorectal primary surgery
Exclusion Criteria
- •unfit patients with dementia
Outcomes
Primary Outcomes
ctDNA level
Time Frame: 3-6 months
residual disease measured by sequential blood draws
Secondary Outcomes
No secondary outcomes reported
Investigators
Pirkko-Liisa Kellokumpu-Lehtinen
professor
Tampere University Hospital